{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:20:03Z","timestamp":1779200403042,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hexal AG, a Sandoz company, part of the Novartis group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>While reasons for non-adherence in children requiring growth hormone (GH) replacement (GH-Rx) are well researched, few studies have investigated adherence in adult GH deficient patients. Against the background of the adverse medical sequelae of untreated severe GH deficiency (GHD) in adults, we explored adherence to GH-Rx and associated factors in this patient group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Cross-sectional analysis including 107 adult patients with severe GHD on GH-Rx, 15 untreated GDH patients and 19 who had discontinued therapy. Patients completed self-developed ad hoc surveys on adherence to medication and GH-Rx, specific beliefs about GH-Rx, side effects and burden of injection, reasons for never receiving or dropping out of therapy, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Adherence to GH-Rx was high (mean 15.8\/18 points on the self-developed adherence score) and significantly correlated with general medication adherence. Higher age was significantly associated with better adherence to GH-Rx, while injection side effects, duration of treatment or device used were not. The most frequent reasons for not being on GH-Rx apart from medical reasons included fear of side effects, lack of belief in treatment effects and dislike of injections. In patients not on GH-Rx, the proportion of patients in employment was significantly smaller than in the treatment group, despite similar age and comorbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Adherence to GH-Rx was high for those patients on therapy. Instead of focusing on improving adherence in those adults already on GH-Rx, efforts should be undertaken to ally fear of side effects and provide education on positive treatment effects for those eligible but not receiving therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-020-01046-y","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T19:02:36Z","timestamp":1590087756000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients\u2018 perspective"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-0261","authenticated-orcid":false,"given":"Ilonka","family":"Kreitschmann-Andermahr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Unger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Streetz-van der Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Karges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Szybowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina","family":"Sauerwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Zopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Grzywotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heide","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian J.","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"1046_CR1","unstructured":"World Health Organisation (2003) Adherence to long-term therapies: evidence for action, WHO. https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_introduction.pdf"},{"issue":"12","key":"1046_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1507\/endocrj.EJ15-0337","volume":"62","author":"L Giovannini","year":"2015","unstructured":"Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G (2015) Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J 62(12):1037\u20131048. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0337","journal-title":"Endocr J"},{"key":"1046_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ghir.2019.06.003","volume":"46\u201347","author":"F De Cobelli","year":"2019","unstructured":"De Cobelli F, Rossini A, Esposito A, Canu T, Manzoni G, Del Maschio A, Rubinacci A, Sirtori M, Losa M, Lanzi R, Perseghin G (2019) Short-term evaluation of cardiac morphology, function, metabolism and structure following diagnosis of adult-onset growth hormone deficiency. Growth Horm IGF Res 46\u201347:50\u201354. https:\/\/doi.org\/10.1016\/j.ghir.2019.06.003","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"1046_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/eje-16-0875","volume":"176","author":"M Elbornsson","year":"2017","unstructured":"Elbornsson M, Horvath A, Gotherstrom G, Bengtsson BA, Johannsson G, Svensson J (2017) Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 176(2):99\u2013109. https:\/\/doi.org\/10.1530\/eje-16-0875","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1046_CR5","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1210\/jc.2013-2415","volume":"98","author":"EM Erfurth","year":"2013","unstructured":"Erfurth EM (2013) Update in mortality in GH-treated patients. J Clin Endocrinol Metab 98(11):4219\u20134226. https:\/\/doi.org\/10.1210\/jc.2013-2415","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1046_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/03007995.2018.1546682","volume":"35","author":"J Loftus","year":"2019","unstructured":"Loftus J, Camacho-Hubner C, Hey-Hadavi J, Goodrich K (2019) Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency. Curr Med Res Opin 35(6):963\u2013973. https:\/\/doi.org\/10.1080\/03007995.2018.1546682","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1046_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/s0008-6363(99)00345-4","volume":"45","author":"KJ Osterziel","year":"2000","unstructured":"Osterziel KJ, Bode-Boger SM, Strohm O, Ellmer AE, Bit-Avragim N, Hanlein D, Ranke MB, Dietz R, Boger RH (2000) Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res 45(2):447\u2013453. https:\/\/doi.org\/10.1016\/s0008-6363(99)00345-4","journal-title":"Cardiovasc Res"},{"issue":"5","key":"1046_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/eje-11-1072","volume":"166","author":"M Elbornsson","year":"2012","unstructured":"Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J (2012) Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166(5):787\u2013795. https:\/\/doi.org\/10.1530\/eje-11-1072","journal-title":"Eur J Endocrinol"},{"issue":"8649","key":"1046_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/s0140-6736(89)92328-3","volume":"1","author":"JO Jorgensen","year":"1989","unstructured":"Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS (1989) Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1(8649):1221\u20131225. https:\/\/doi.org\/10.1016\/s0140-6736(89)92328-3","journal-title":"Lancet"},{"issue":"26","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/nejm198912283212605","volume":"321","author":"F Salomon","year":"1989","unstructured":"Salomon F, Cuneo RC, Hesp R, Sonksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321(26):1797\u20131803. https:\/\/doi.org\/10.1056\/nejm198912283212605","journal-title":"N Engl J Med"},{"issue":"1","key":"1046_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4158\/ep13194.Or","volume":"20","author":"BK Aydin","year":"2014","unstructured":"Aydin BK, Aycan Z, Siklar Z, Berberoglu M, Ocal G, Cetinkaya S, Bas VN, Kendirci HN, Cetinkaya E, Darcan S, Goksen D, Evliyaoglu O, Sukur M, Bas F, Darendeliler F (2014) Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract 20(1):46\u201351. https:\/\/doi.org\/10.4158\/ep13194.Or","journal-title":"Endocr Pract"},{"issue":"10","key":"1046_CR12","doi-asserted-by":"publisher","first-page":"e0206009","DOI":"10.1371\/journal.pone.0206009","volume":"13","author":"P van Dommelen","year":"2018","unstructured":"van Dommelen P, Koledova E, Wit JM (2018) Effect of adherence to growth hormone treatment on 0\u20132 year catch-up growth in children with growth hormone deficiency. PLoS ONE 13(10):e0206009. https:\/\/doi.org\/10.1371\/journal.pone.0206009","journal-title":"PLoS ONE"},{"issue":"4","key":"1046_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000493211","volume":"90","author":"S Graham","year":"2018","unstructured":"Graham S, Weinman J, Auyeung V (2018) Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr 90(4):221\u2013227. https:\/\/doi.org\/10.1159\/000493211","journal-title":"Horm Res Paediatr"},{"key":"1046_CR14","doi-asserted-by":"publisher","DOI":"10.1055\/a-0956-1919","author":"F Amereller","year":"2019","unstructured":"Amereller F, Schilbach K, Schopohl J, Stormann S (2019) Adherence, attitudes and beliefs of growth hormone deficient patients:&nbsp; a questionnaire-based cohort study. Exp Clin Endocrinol Diabetes. https:\/\/doi.org\/10.1055\/a-0956-1919","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"1046_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1210\/jcem.87.2.8216","volume":"87","author":"ML Hartman","year":"2002","unstructured":"Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87(2):477\u2013485. https:\/\/doi.org\/10.1210\/jcem.87.2.8216","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1331\/JAPhA.2011.09154","volume":"51","author":"SM Lavsa","year":"2011","unstructured":"Lavsa SM, Holzworth A, Ansani NT (2011) Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003) 51(1):90\u201394. https:\/\/doi.org\/10.1331\/JAPhA.2011.09154","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"3","key":"1046_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bcp.12194","volume":"77","author":"TM Nguyen","year":"2014","unstructured":"Nguyen TM, La Caze A, Cottrell N (2014) What are validated self-report adherence scales really measuring? A systematic review. Br J Clin Pharmacol 77(3):427\u2013445. https:\/\/doi.org\/10.1111\/bcp.12194","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1046_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10(5):348\u2013354","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"1046_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1891\/106137407783095757","volume":"15","author":"J Risser","year":"2007","unstructured":"Risser J, Jacobson TA, Kripalani S (2007) Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas 15(3):203\u2013219","journal-title":"J Nurs Meas"},{"issue":"2","key":"1046_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s0738-3991(98)00107-4","volume":"37","author":"BL Svarstad","year":"1999","unstructured":"Svarstad BL, Chewning BA, Sleath BL, Claesson C (1999) The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 37(2):113\u2013124. https:\/\/doi.org\/10.1016\/s0738-3991(98)00107-4","journal-title":"Patient Educ Couns"},{"issue":"3","key":"1046_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1751-7117.2000.tb00211.x","volume":"15","author":"MT Kim","year":"2000","unstructured":"Kim MT, Hill MN, Bone LR, Levine DM (2000) Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs 15(3):90\u201396","journal-title":"Prog Cardiovasc Nurs"},{"issue":"3","key":"1046_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s0920-9964(99)00130-9","volume":"42","author":"K Thompson","year":"2000","unstructured":"Thompson K, Kulkarni J, Sergejew AA (2000) Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42(3):241\u2013247. https:\/\/doi.org\/10.1016\/s0920-9964(99)00130-9","journal-title":"Schizophr Res"},{"issue":"6","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/cen.13030","volume":"84","author":"MK Auer","year":"2016","unstructured":"Auer MK, Stieg MR, Hoffmann J, Stalla GK (2016) Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? Clin Endocrinol (Oxf) 84(6):862\u2013869. https:\/\/doi.org\/10.1111\/cen.13030","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1046_CR24","doi-asserted-by":"publisher","first-page":"e50537","DOI":"10.1371\/journal.pone.0050537","volume":"7","author":"JA Glombiewski","year":"2012","unstructured":"Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E (2012) Medication adherence in the general population. PLoS ONE 7(12):e50537. https:\/\/doi.org\/10.1371\/journal.pone.0050537","journal-title":"PLoS ONE"},{"issue":"3","key":"1046_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","volume":"31","author":"KS Ingersoll","year":"2008","unstructured":"Ingersoll KS, Cohen J (2008) The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 31(3):213\u2013224. https:\/\/doi.org\/10.1007\/s10865-007-9147-y","journal-title":"J Behav Med"},{"issue":"2","key":"1046_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1353\/hpu.0.0314","volume":"21","author":"DL Frankenfield","year":"2010","unstructured":"Frankenfield DL, Wei II, Anderson KK, Howell BL, Waldo D, Sekscenski E (2010) Prescription medication cost-related non-adherence among Medicare CAHPS respondents: disparity by Hispanic ethnicity. J Health Care Poor Underserved 21(2):518\u2013543. https:\/\/doi.org\/10.1353\/hpu.0.0314","journal-title":"J Health Care Poor Underserved"},{"issue":"2","key":"1046_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00002030-200201250-00017","volume":"16","author":"JC Walsh","year":"2002","unstructured":"Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16(2):269\u2013277. https:\/\/doi.org\/10.1097\/00002030-200201250-00017","journal-title":"AIDS"},{"issue":"6","key":"1046_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1161\/01.hyp.2.6.757","volume":"2","author":"RB Haynes","year":"1980","unstructured":"Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J (1980) Can simple clinical measurements detect patient noncompliance? Hypertension 2(6):757\u2013764. https:\/\/doi.org\/10.1161\/01.hyp.2.6.757","journal-title":"Hypertension"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-020-01046-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:26:50Z","timestamp":1621553210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-020-01046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s11102-020-01046-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"21 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Martin Bidlingmaier, Ilonka Kreitschmann-Andermahr and Christian Strasburger are members of the German PATRO Board and, as such, have received consulting and speaker honoraria as well as travel reimbursements. Agnieszka Grzywotz, Bernadette Schr\u00f6der and Sonja Siegel have received conference travel reimbursements from Hexal, Germany for attending PATRO board investigator meetings. Heide Sommer is an employee of Hexal, Germany. All other authors report no conflict of interest pertaining to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}